<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04810091</url>
  </required_header>
  <id_info>
    <org_study_id>2019-1205</org_study_id>
    <secondary_id>NCI-2021-00852</secondary_id>
    <secondary_id>2019-1205</secondary_id>
    <nct_id>NCT04810091</nct_id>
  </id_info>
  <brief_title>Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor</brief_title>
  <official_title>TELEHEART: Telotristat Ethyl in a Heart Biomarker Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial compares the effect of telotristat ethyl and the current standard of&#xD;
      care somatostatin analog therapy or somatostatin analog therapy alone in treating patients&#xD;
      with neuroendocrine tumor that has spread to other places in the body (metastatic).&#xD;
      Telotristat ethyl and somatostatin analog therapy may help to control carcinoid syndrome and&#xD;
      carcinoid heart disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To estimate the percent change in N-terminal pro B-type natriuretic peptide (NT-proBNP) at&#xD;
      6 month visit from baseline after initiation of study drug in each arm and to compare the&#xD;
      percent change between the two study arms.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the change in functional capacity from baseline at 3 and 6 month visits as&#xD;
      assessed by a 6 minute walk test (6MWT) in each arm.&#xD;
&#xD;
      II. To evaluate changes in echocardiographic parameters (Carcinoid Valvular Heart Disease&#xD;
      [CVHD] score, global longitudinal myocardial strain assessment of the left and right&#xD;
      ventricle/tricuspid annular plane systolic excursion [TAPSE]) from baseline to 3 and 6 month&#xD;
      visits in each arm.&#xD;
&#xD;
      III. To evaluate the change from baseline to 3 and 6 month visits in plasma&#xD;
      5-hydroxyindoleacetic acid (5-HIAA) levels in each arm.&#xD;
&#xD;
      IV. To evaluate the change from baseline to 3 and 6 month visits in high sensitivity troponin&#xD;
      T in each arm.&#xD;
&#xD;
      V. To evaluate the change from baseline to 3 and 6 month visits in health related quality of&#xD;
      life with using the MD Anderson Symptom Inventory (MDASI) in each arm.&#xD;
&#xD;
      VI. To evaluate compliance of medications.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM A: Patients receive telotristat ethyl orally (PO) three times daily (TID) and&#xD;
      somatostatin analog therapy (SSA) for 6 months in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      ARM B: Patients receive placebo PO TID and SSA for 6 months in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up for 30 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in N-terminal pro B-type natriuretic peptide (NT-proBNP)</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6-minute walk test (6MWT)</measure>
    <time_frame>Baseline to 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Carcinoid Valvular Heart Disease (CVHD) score</measure>
    <time_frame>Baseline to 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (significant change or non-significant change) in global longitudinal myocardial strain assessment of the left and right ventricle</measure>
    <time_frame>Baseline to 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tricuspid annular plane systolic excursion (normal vs. abnormal)</measure>
    <time_frame>Baseline to 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma 5-HIAA levels</measure>
    <time_frame>Baseline to 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in high sensitivity troponin T</measure>
    <time_frame>Baseline to 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life questionnaire</measure>
    <time_frame>Baseline to 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Locally Advanced Well Differentiated Neuroendocrine Neoplasm</condition>
  <condition>Metastatic Well Differentiated Neuroendocrine Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm A (telotristat ethyl, SSA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive telotristat ethyl PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (placebo, SSA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive placebo PO TID and SSA for 6 months in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm B (placebo, SSA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (telotristat ethyl, SSA)</arm_group_label>
    <arm_group_label>Arm B (placebo, SSA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telotristat Ethyl</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (telotristat ethyl, SSA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are &gt;= 18 years old will be eligible for the study&#xD;
&#xD;
          -  Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor&#xD;
             and/or locally/regionally advanced neuroendocrine tumor&#xD;
&#xD;
          -  Documented history of carcinoid syndrome based on clinical parameters&#xD;
&#xD;
          -  Currently receiving stable-dose somatostatin analog (SSA) therapy defined as &gt;= 2&#xD;
             months&#xD;
&#xD;
               -  Dose of long-acting release (LAR) or depot SSA therapy and on at least:&#xD;
&#xD;
                    -  Octreotide LAR at 30 mg every 4 weeks&#xD;
&#xD;
                    -  Lanreotide depot at 120 mg every 4 weeks&#xD;
&#xD;
                    -  Patients who cannot tolerate SSA therapy at a level indicated above will be&#xD;
                       allowed to enter at their highest tolerated dose&#xD;
&#xD;
          -  Ability and willingness to provide written informed consent&#xD;
&#xD;
          -  Patients of childbearing potential must agree to use an adequate method of&#xD;
             contraception during the study and for 30 days after the last dose of telotristat&#xD;
             ethyl&#xD;
&#xD;
               -  Childbearing potential is defined as those who have not undergone surgical&#xD;
                  sterilization (eg. documented hysterectomy, tubal ligation, or bilateral&#xD;
                  salpingo-oophorectomy) or those who are not considered postmenopausal (defined as&#xD;
                  12 months of spontaneous amenorrhea).&#xD;
&#xD;
               -  Adequate methods of contraception, defined as having a failure rate of &lt; 1% per&#xD;
                  year, for patients or their partner include the following: condom with&#xD;
                  spermicidal gel, diaphragm with spermicidal gel, intrauterine device, surgical&#xD;
                  sterilization, vasectomy, oral contraceptive pill, depo-progesterone injections,&#xD;
                  progesterone implant (ie, Implanon), patch (Ortho Evra), NuvaRing, and&#xD;
                  abstinence. If a patient is not sexually active but becomes active, he or his&#xD;
                  partner should use medically accepted forms of contraception&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous exposure to telotristat ethyl (XERMELO)&#xD;
&#xD;
          -  History of active treatment for malignancy, other than neuroendocrine tumor&#xD;
             (malignancies that in the opinion of the Investigator are considered cured, may&#xD;
             participate)&#xD;
&#xD;
          -  Treatment with any tumor directed therapy, including interferon, chemotherapy,&#xD;
             mechanistic target of rapamycin (mTOR) inhibitors &lt; 4 weeks prior to screening, or&#xD;
             hepatic embolization, radiotherapy, peptide receptor radionuclide therapy, and/or&#xD;
             tumor debulking &lt; 12 weeks prior to screening&#xD;
&#xD;
          -  History of short bowel syndrome or other known causes of diarrhea unrelated to&#xD;
             carcinoid syndrome&#xD;
&#xD;
          -  Clinically significant (as per primary investigators judgement) cardiac arrhythmia,&#xD;
             bradycardia, tachycardia that would compromise patient safety or the outcome of the&#xD;
             study&#xD;
&#xD;
          -  Estimated glomerular filtration rate estimated glomerular filtration rate (eGFR) &lt; 30&#xD;
             ml/min&#xD;
&#xD;
          -  Hepatic laboratory values of aspartate transaminase (AST) or alanine aminotransferase&#xD;
             (ALT):&#xD;
&#xD;
               -  &gt; 5 x upper limit of normal (ULN) if patient has documented history of hepatic&#xD;
                  metastases; or&#xD;
&#xD;
               -  &gt; 2.5 x ULN if no liver metastases are present&#xD;
&#xD;
          -  Pregnant or lactating patients&#xD;
&#xD;
          -  Patients receiving everolimus due to poor response to SSA&#xD;
&#xD;
          -  Life expectancy &lt; 6 months&#xD;
&#xD;
          -  Any other clinically significant laboratory abnormality that would compromise patient&#xD;
             safety or the outcome of the study as per primary investigators judgement&#xD;
&#xD;
          -  Any clinically significant and/or uncontrolled cardiac-related abnormality that would&#xD;
             compromise patient safety or the outcome of the study including as per primary&#xD;
             investigators judgement, but not limited to:&#xD;
&#xD;
               -  Arrhythmia causing hemodynamic compromise&#xD;
&#xD;
               -  Symptomatic severe valvular disease&#xD;
&#xD;
               -  Symptomatic congestive heart failure classified by New York Heart Association&#xD;
                  (NYHA) class IV&#xD;
&#xD;
               -  Evidence of ischemia on electrocardiography (ECG) with chest pain&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
          -  Current complaints of persistent constipation or history of chronic constipation,&#xD;
             bowel obstruction or fecaloma within the past 6 months&#xD;
&#xD;
          -  Investigator assessment of known history and/or uncontrolled hepatitis B surface&#xD;
             antigen (HBsAg), hepatitis C antibody (HCV Ab), or human immunodeficiency virus&#xD;
             (HIV)-1 or HIV-2&#xD;
&#xD;
          -  History of substance or alcohol abuse (Diagnostic and Statistical Manual of Mental&#xD;
             Disorders 5th edition [DSM-V] Criteria for Substance-Related Disorders) within the&#xD;
             past 2 years&#xD;
&#xD;
          -  History of galactose intolerance, deficiency of Lapp lactase, or glucose-galactose&#xD;
             malabsorption&#xD;
&#xD;
          -  Receipt of any investigational agent or study treatment (other treatment nor approved&#xD;
             by Food and Drug Administration [FDA] for carcinoid syndrome or carcinoid heart&#xD;
             disease) within the past 30 days&#xD;
&#xD;
          -  Existence of any surgical or medical condition that, in the judgment of the&#xD;
             Investigator, might compromise patient safety or the outcome of the study&#xD;
&#xD;
          -  Presence of any clinically significant findings (relative to the patient population)&#xD;
             during review of medical history or upon PE that, in the investigator's opinion, would&#xD;
             compromise patient safety or the outcome of the study (e.g., psychiatric&#xD;
             illness/social situations that would limit compliance with study requirements)&#xD;
&#xD;
          -  Unable or unwilling to communicate or cooperate with the Investigator for any reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saamir A Hassan</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saamir A. Hassan</last_name>
      <phone>713-745-6793</phone>
      <email>sahassan1@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Saamir A. Hassan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

